Figure 6. Effect of INT-1B3 on subcutaneous human melanoma A2058 tumor growth in immune-compromized mice.

Human melanoma A2058 tumor cells (5 × 10⁶) in 0.1-mL PBS were injected subcutaneously in the flank BALBc/nude mice. After eight days, animals were randomized to experimental groups based on subcutaneous tumor size (median ~150 mm³; established subcutaneous tumor model). Animals were then treated with either vehicle (PBS, i.p.; black) or INT-1B3 (3 mg/kg/administration, i.v.; green) daily for five days the first week, then twice weekly for the next two weeks. Subcutaneous tumor volumes (expressed as mm³) were calculated throughout the study based on caliper-aided tumor measurements and applying the following formula: (length × width²)/2. (A) Time-dependent evolution of tumor volumes (median values expressed as mm³). (B) on Day 22, individual tumor volumes, median (horizontal bar) and interquartile range (vertical error bar), are presented for the indicated experimental groups. A 2-tailed non-parametric Mann–Whitney statistical analysis was performed for INT-1B3 (p = 0.0062) as compared to PBS-treated group, with n = 7 and 5 for PBS and INT-1B3 groups, respectively.